Greenblatt D J, von Moltke L L, Harmatz J S, Shader R I
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and New England Medical Center, Boston, Mass 02111, USA.
J Clin Psychiatry. 1998;59 Suppl 15:19-27.
Selective serotonin reuptake inhibitors and related antidepressant compounds have the secondary pharmacologic property of inhibiting the activity of human cytochrome P450 enzymes responsible for the oxidative metabolism of many drugs. A number of clinically important pharmacokinetic drug interactions are a consequence of these cytochrome inhibiting effects. This review evaluates the clinical implications of the metabolic profiles of the newer antidepressants, the relative activities of various new antidepressants as inhibitors of human cytochrome P450, and the various in vivo and in vitro methodologies that can be used for identification and quantification of drug interactions.
选择性5-羟色胺再摄取抑制剂及相关抗抑郁化合物具有抑制负责多种药物氧化代谢的人细胞色素P450酶活性的次要药理特性。许多具有临床重要性的药代动力学药物相互作用就是这些细胞色素抑制作用的结果。本综述评估了新型抗抑郁药代谢谱的临床意义、各种新型抗抑郁药作为人细胞色素P450抑制剂的相对活性，以及可用于识别和定量药物相互作用的各种体内和体外方法。
